Article type : Research Article

Melatonin induces Nrf2-HO-1 reprogramming and corrections in hepatic core clock oscillations in Non-alcoholic fatty liver disease

Running title: Melatonin improves clock genes oscillations in NAFLD

Apeksha Joshi[1], Kapil K Upadhyay[2], Aliasgar Vohra[1], Kavita Shirsath[1], Ranjitsinh Devkar[1*]

[1]Division of Chronobiology and Metabolic Endocrinology, Department of Zoology, Faculty of Science, The Maharaja Sayajirao University of Baroda, Vadodara-390002, Gujarat, India.

[2] Department of Internal medicine, Division of Gastroenterology and Hepatology, University of Michigan Medical School, Ann Arbor, Michigan, 48109, USA.

*rv.devkar-zoo@msubaroda.ac.in

Abstract

Melatonin pleiotropically regulates physiological events and has a putative regulatory role in circadian clock desynchrony mediated Non-alcoholic fatty liver disease (NAFLD). In this study, we investigated perturbations in hepatic circadian clock gene and Nrf2-HO-1 oscillations in conditions of high fat high fructose (HFHF) diet and/or jet lag (JL) mediated NAFLD. Melatonin treatment (100µM) to HepG2 cells led to an improvement in oscillatory pattern of clock genes (*Clock, Bmal1* and *Per*) in oleic acid (OA) induced circadian desynchrony, while *Cry, Nrf2* and *HO-1* remain oblivious of melatonin treatment that was also validated by circwave analysis. C57BL/6J mice subjected to HFHF and/or JL, and treated with melatonin showed an improvement in profile of lipid regulatory genes (*CPT-1,*

PPARa and SREBP-1c), liver function (AST and ALT) and histomorphology of fatty liver. A detailed scrutiny revealed that hepatic mRNA and protein profiles of Bmal1 (at ZT6) and Clock (at ZT12) underwent corrective changes in oscillations but moderate corrections were recorded in other components of clock genes (Per1, Per2 and Cry2). Melatonin induced changes in oscillations of anti-oxidant genes (Nrf2, HO-1 and Keap1) subtly contributed in overall improvement in NAFLD recorded herein. Taken together, melatonin induced reprograming of hepatic core clock and Nrf2-HO-1 genes leads to an improvement in HFHF/JL induced NAFLD.

Keywords

Melatonin, NAFLD, clock genes, Nrf2-HO-1.

Abbreviations

NAFLD-Non-alcoholic fatty Liver disease

HFHF-high fat high fructose

JL- jet lag

OA- Oleic acid

Clock- circadian locomotor output cycles kaput

Bmal1- brain and muscle ARNT-like 1

Per1-2-period circadian protein homolog 1 and 2

Cry1-2- cryptochrome circadian regulator 1

Nrf2- nuclear factor erythroid 2-related factor 2

Keap1- Kelch-like ECH-associated protein 1

HO-1- Heme oxygenase 1

ARE- Antioxidant response elements

ZT- Zeitgebers time

SCN- Suprachiasmatic Nucleus

Introduction

Circadian rhythms are the internal biological clock that orchestrates various physiological events of metabolic processes in mammals [1]. The Suprachiasmatic nucleus (SCN) is the central pacemaker of the biological clock, while peripheral clocks in various organs are operated by autoregulatory expression of clock genes [2]. The molecular network comprises of circadian locomotor output cycles kaput (Clock) and brain and muscle ARNT-like 1 (Bmal1) as activators, and period circadian protein homolog 1 (Per1), Per2, cryptochrome circadian regulator 1 (Cry1), and Cry2 as repressors, which work in transcriptional-translational feedback loop [3]. Like various other organs, liver has its own circadian rhythm and clock gene expression patterns. Hepatic clock can be modulated by external clues,

wherein light serves as an important synchroniser. However, food also acts as a crucial clue which reprograms the hepatic clock [4,5]. Clock genes expression is known to differ before and after feeding in tissues such as hypothalamus, liver, and skeletal muscles [6]. High fat diet leads to alterations in the expression and cycling of canonical circadian clock genes, nuclear receptors and clock-controlled genes [6–8]. Palmitate, a saturated fatty acid at low doses inhibits the molecular clock activity and destabilises protein-protein interaction between Bmal1 and Clock [9–11].

Epidemiological studies have shown that shift workers with frequent change in timings over a considerable span and transcontinental travellers exposed to photoperiodic changes amounting to jetlag have high risk to metabolic disorders [12,13]. Clock gene mutant animals display impaired glucose and lipid metabolism and are susceptible to diet-induced obesity and metabolic dysfunction [14]. Also, there are reports on marked activation in expression of Per1 and Per2 and suppression of clock expression in chronic jetlagged CBA/N mice [15]. Chronic jetlag has also been reported to aggravate steatohepatitis and even induce hepatocellular carcinoma in $Fxr^{-/-}$ mice [16]. These compelling evidences points towards a strong connection between the circadian clock and metabolic homeostasis.

NAFLD is associated with hepatic dysregulation of energy metabolism, lipid accumulation, oxidative stress and inflammation [17]. The pathophysiology of NAFLD is best explained by multiple hit model, wherein oxidative stress plays a primary role in initiating hepatic damage [18]. The cellular response against oxidative stress is mainly regulated by the Kelch-like ECH-associated protein 1 (Keap1) - nuclear factor erythroid 2-related factor 2 (Nrf2) - antioxidant response elements (ARE) genes [19]. In conditions of NAFLD, Nrf2 has been shown to be downregulated which is accompanied by an increased oxidative stress [20]. Xu and co-workers had investigated the expression patterns for antioxidant genes in mice liver and found that Nrf2 expression exhibited circadian variations that altered cellular oxidative stress response [21]. Circadian-clock-dependent regulation of redox status, ROS homeostasis and antioxidant defence has been investigated by various research groups wherein, evidences suggesting Bmal1 as a transcriptional regulator of Nrf2 has been showcased [22–25].

Melatonin is secreted by pineal gland, responsible for regulating the circadian rhythm. However, there is an increasing evidence showing its involvement in many other key physiological functions [26–28]. Melatonin is known to protect against obesity and hepatic

steatosis by improving lipid dysmetabolism and attenuating inflammation in high fat diet fed mice [29,30]. Melatonin attenuates dysregulation of the circadian clock pathway in mice with CCl_4 induced liver fibrosis. One of the recent findings have shown regulatory role of melatonin in lipid homeostasis and clock gene regulation in mice exposed to constant light [31].

Though, major body of evidence shows correlation of circadian clock with NAFLD in clock gene ablation models, the role of clock genes and melatonin in metabolic rewiring under conditions of HFHF and/or JL models is a lacuna in the available scientific information. On the other hand, role of melatonin in modulating circadian rhythm is well established but its role in re-entrainment of altered circadian cycle by HFHF and/or JL in NAFLD is not known. This study is the first to investigate in detail the shift in clock gene oscillations and Nrf2-HO-1 in HFHF and/or JL induced NAFLD, wherein merits of exogenous melatonin in making corrective changes has been contemplated.

Material and methods

Chemicals and reagents Chemicals for cell culture like Dulbecco's modified eagle's medium (DMEM), fetal bovine serum (FBS), trypsin phosphate versene glucose (TPVG), bovine serum albumin (BSA) and antibiotic-antimycotic solution were purchased from Hi-media laboratories (Mumbai, India). TRIzol, SYBR select master mix, anti-CLOCK (PA1-520) and anti-BMAL1(PA1-46118) antibodies were procured from Invitrogen (Thermo Fisher Scientific, USA). iScript cDNA synthesis kit and Clarity Western ECL substrate were procured from Bio-Rad Laboratories (CA, USA). Antibodies against Nrf2 (12721S), HO-1 (70081S), β-actin (4970S) and anti-rabbit secondary antibody (7074P2) were purchased from Cell Signalling Technology (MA, USA). Antibody against Keap1 (ab139729) was purchased from Abcam (MA, USA). RNA Later stabilizing solution was purchased from Ambion Inc. (Thermo Fisher Scientific, USA). Melatonin, Haematoxylin, eosin and Oleic acid (OA) were purchased from Sigma Aldrich (MO, USA). Methanol, dimethyl sulphoxide (DMSO) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) were purchased from Sisco research laboratory Pvt. Ltd. (Mumbai, India).

Maintenance of HepG2 cells and their treatment Human Hepatoma (HepG2) cells were procured from National Centre for Cell Science (NCCS, Pune, India). Cells were cultured in DMEM containing 10% fetal bovine serum (FBS) and 1% antibacterial-antimycotic solution

at 37°C in a humidified atmosphere with 5 % CO_2. Passaging was done using 1X TPVG at about 80% confluency.

Treatment with Oleic acid conjugated with BSA and/or melatonin OA stock solution was prepared as described previously [32]. 100 mM of OA was conjugated with 10% BSA to obtain 10 mM OA-conjugated BSA stock solution. Further dilution was done in culture media to obtain working solution. Melatonin was dissolved in media to obtain a stock solution of 1 mM. Later, HepG2 cells were synchronized by serum shock (50% Fetal bovine serum) for 2 h and then treated with OA alone and in combination with Melatonin for 24h. Following treatment, cells were collected for further analysis.

Cytotoxicity analysis HepG2 cells were seeded in 96-well plate (10^4 cells/well) in DMEM and exposed to various doses of OA (0.5-2 mM) and/or melatonin (5-1000 µM). After 24h, MTT (0.5 mg/ml) was added and cells were incubated for 4h. Resultant formazan crystals were solubilized in 100 µl DMSO solution and absorbance was measured at 540 nm using multimode reader synergy HTX (Bio-Tek instruments, Inc., Winooski, VT).

Intracellular lipid accumulation HepG2 cells were treated with OA (0.5 mM) and/or Melatonin (100 µM) for 24 h, fixed with 4% paraformaldehyde and washed with PBS. Cells were stained with Oil red O and photographed using Floid cell imaging station (Life technologies, USA). To quantify Oil red O levels, 100% isopropanol was added in each well and measured at 510 nm using Synergy HTX Multi-Mode Microplate Reader (Bio-Tek instruments, Inc., Winooski, VT).

Intracellular oxidative stress HepG2 cells treated with OA (0.5 mM) and/or Melatonin (100 µM) for 24 h were stained with 10 µM 2, 7-dichlorodihydrofluoroscein diacetate (CM-H2-DCFDA) at 37 °C for 30 min. Cells were photographed (Floid cell imaging station; Life technologies, USA) and the intracellular fluorescence quantified using Image J software (NIH, Bethesda).

Mitochondrial membrane potential Cells were seeded in 6 wells plate and treated as mentioned earlier. Later, cells were washed with 1X PBS and incubated with JC-1 (5 µg/ml) in pre-warmed 1X PBS for 30 min at 37 °C. Cells were photographed using Floid cell imaging station and fluorescent intensity was quantified using ImageJ software**.**

Animal studies C57BL/6J male mice (total=140, 6–8 weeks of age) were purchased from ACTREC Mumbai and maintained as per CPCSEA (The committee for the Purpose of Control and Supervision of Experiments on Animals) standard guidelines (23 ± 2 °C, LD 12:12, laboratory chow and water ad libitum). Protocol was prior approved by Institutional Animal Ethical Committee (IAEC; Approval no. MSU-Z/IAEC/04-2017) and experiments were conducted in CPCSEA approved animal house facility of Department of Zoology, The Maharaja Sayajirao University of Baroda, Vadodara, Gujarat, India (827/GO/Re/S/04/ CPCSEA).

Experimental groups for animal studies Followed by a week-long acclimatization, animals were randomly divided into 7 groups (n=20 per group) viz. (i) control, (ii) HFHF (high fat + 20% Fructose diet), (iii) Jetlag (chow diet and JL - jetlag photoperiodic regimen) and (iv) HFHF+JL and maintained for 16 weeks. From 8 to 16 weeks, Groups ii, iii and iv were dosed intraperitoneally with melatonin (10 mg/kg at ZT=10) daily. Dose of 10mg/kg body weight was preferred as it is widely used in rodent models [33]. JL was induced according a published method [16] wherein, mice were transferred from Room 1 (7:00h 19:00h light/19:00h to 7:00 h dark period) to Room 2 (11:00h to 23:00h dark/23:00h to 11:00h light period) resulting in phase advance of 8h (lights off at ZT4) and transferring back to Room 1 resulting in a phase delay of 8h (lights off at ZT20) (Fig. 1) on Mondays and Thursdays, respectively. Food intake and body weight were recorded every alternate day (Supplementary figure 6). At the end of 16 weeks, mice were euthanized with mild isoflurane at different time points (ZT=0, 6, 12, 18, 24). Whole blood was centrifuged at 3000 rpm for 10 min at 4°C and serum was isolated and stored. Later, liver tissue samples were snap frozen (ORO staining), stored in 10% formalin (for histopathology), RNA Later (for mRNA studies) and -80°C (for immunoblot studies).

Serum biochemical analysis Levels of circulating enzymes indicative of liver function (AST and ALT) and serum lipid profile (TL, TC, TG, LDL, VLDL, CHL/HDL and LDL/HDL ratio) were estimated using commercially available kits (Reckon Diagnostic kits, Vadodara, Gujarat, India).

Histopathological analysis Formalin fixed liver samples were dehydrated and embedded in paraffin wax blocks, cut into 5 μm thick sections, stained with haematoxylin and eosin (H&E). Observations were recorded and photographed (Leica DM 750 microscope).

Investigators blinded to this study conducted scoring of ballooning hepatocytes sections of control and treated mice [34].

Oil Red O staining analysis 4-μm-thick frozen liver sections were washed in deionized water for 3 times followed by blocking with oil red O solution for 10 min at room temperature, then washed with deionized water and stained with hematoxylin. In the end, tissue sections were mounted in glycerin gelatin and analyzed by light microscopy (Leica DM 750 microscope).

Glucose metabolism analysis At the end of 15th week, mice were fasted for 6 h and an intraperitoneal (IP) glucose tolerance test (IGTT) was performed. An IP glucose solution (2 g glucose/kg body weight) was administered, followed by blood glucose monitoring at 30, 60, 90, and 120 min using Accucheck active glucometer.

mRNA studies by RT-qPCR Total RNA was isolated from HepG2 cells and liver tissue samples using TRIzol reagent and was reverse transcribed into cDNA using iScript cDNA Synthesis kit. The mRNA expression of various genes was quantified by qPCR analysis (QuantStudio 3, Life Technologies, CA, USA) using SYBR Select Master Mix. Gene-specific human and mice primers used for this study are listed in table 1. The data were normalized to GAPDH and analysed using $2^{-\Delta\Delta CT}$ method.

Immunoblot analysis Autopsy of liver from control and experimental groups of mice were collected and stored in liquid nitrogen. For extracting total protein lysate, tissue was homogenized in RIPA buffer (50 mM tris (pH 8.0), 150 mM NaCl, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 1% triton-X-100) containing protease inhibitor cocktail (Sigma Aldrich, USA) and 1mM PMSF, followed by incubation at 4°C for 2 h. The lysate was centrifuged at 10,000 rpm at 4°C for 20 min and resultant supernatant was subjected to protein estimation using Bio-Rad protein assay dye reagent (Bio-Rad Laboratories, USA). Later, equal amount of protein (30 μg) was separated using 10% SDS gel electrophoresis and transferred onto PVDF membranes (Bio-Rad, USA) and primary antibodies against Clock (1:500), Bmal1 (1:1000), Nrf2 (1:500), HO-1 (1:1000) and Keap1 (1:1000) were added followed by HRP-linked anti-rabbit secondary antibody (1:5000). Blots were developed using Clarity western ECL reagent (Bio-Rad, CA, USA) and X-ray films. Anti-β-actin antibody (1:5000) was used to determine equivalent loading.

Statistical analysis Data was expressed as mean ± SD. All the groups were compared with control group by one-way analysis of variance (ANOVA) and melatonin treated group was

compared with its respective disease group using two-way ANOVA followed by Turkey's multiple comparison test using Graph Pad Prism 5.0 (CA, USA). Rhythmic variations in clock gene expression were analysed using Circwave software v1.4 (www.hutlab.nl). Amplitudes of curves were calculated as percentage of data mean [difference between the zenith (highest point) and nadir (lowest point) and divided by the data mean (max − min/ mean * 100%)].*P < 0.05, **P < 0.01 and ***P < 0.001 were considered to be significant.

Results

Melatonin improves OA induced fat accumulation in HepG2 cells.

HepG2 cells were treated with OA (0.5 mM) alone or in combination with Melatonin (100 μM). Decrement in cytotoxicity, fat accumulation, oxidative stress and an improved mitochondrial membrane potential were inferred via MTT assay, ORO, DCFDA and JC1 stainings respectively (Supplementary fig. 1,2,3,4). Also, Melatonin treatment accounted for significant (P<0.001) increment in mRNA levels of lipolytic genes (*CPT-1 and PPARα*) and decrement in lipogenic genes (*SREBP-1c*) (P<0.001) (supplementary fig. 5). These findings are in agreement with reports of other research groups [35] and hence forms the basis of our study.

Melatonin synchronizes core clock genes oscillations and antioxidant genes in OA treated HepG2 cells.

To study the potential of melatonin in modifying the circadian clock following OA treatment to HepG2 cells, mRNA levels were studied at 4h intervals (24, 28, 32, 36, 40, 44 and 48 h). Synchronized HepG2 cells showed robust oscillatory pattern of core clock genes (*Clock, Bmal1, Per2, Cry2*) and antioxidant pathway genes (*Nrf2 and HO-1*). After serum shock, cells were treated with OA (0.5 mM) for 24h. Presence of OA dampened the oscillation of *Clock, Bmal1, Per2, Nrf2 and HO-1,* while oscillation of *Cry2* was unaltered. Intriguingly, melatonin treatment significantly improved oscillation of *Bmal1, Clock* and *Per2* (P<0.001). However, expression levels of *Cry2, Nrf2, HO-1* were not adequately corrected (Fig. 2A). Circwave analysis also showed a strong positive shift in amplitude of *Bmal1, Clock* and *Per2* following melatonin treatment. But amplitude of *Cry2, Nrf2 and HO-1* were not restored (Fig. 2B).

Melatonin improves patho-physiological changes in NAFLD.

C57BL/6J mice were subjected to HFHF, JL or combination of both. A significant increase in body weight was noted in HFHF and HFHF+JL group ($P<0.001$), while JL showed no change as compared to control. Further, melatonin treatment accounted for decrement in body weight of HFHF and JL group (Fig. 3). HFHF/JL alone or in combination accounted for significant increment in blood glucose and AUC (Area under curve) ($P<0.001$). Melatonin treatment to these three experimental groups did not account for a decrement in AUC as the values were significantly higher than control group (Fig. 4). The markers of liver function (AST and ALT) were significantly elevated in HFHF, JL and HFHF+JL groups ($P<0.001$). Melatonin treatment accounted for significant decrement ($P<0.001$) in serum AST levels in these experimental groups whereas decrement in ALT levels were recorded only in HFHF and JL groups (Fig. 5A and B). Microscopic evaluations of liver tissue showed hepatocyte ballooning, cellular derangement, and Mallory hyaline in HFHF, JL and HFHF+JL groups, with more prominent changes seen in HFHF+JL group (Supplementary fig. 7). Random scoring of the liver tissue sections revealed that HFHF+JL group accounted for maximum indices of fatty manifestations in liver. Melatonin treatment accounted for significant decrement in indices of hepatic manifestations and intracellular fat accumulation with reparative changes even in HFHF+JL+Mel group (Fig. 5C). HFHF and HFHF+JL groups recorded significant increment in fatty changes in hepatocytes as evidenced by ORO staining, but melatonin treatment showed beneficial effect in decreasing the lipid content in the liver (Suplementary fig. 7).

Melatonin makes corrective changes in mRNA profile of lipid regulatory genes.

Experimental groups viz. HFHF, JL and HFHF+JL showed alterations in lipid profile wherein TG, TC, LDL and VLDL were found to be significantly elevated ($P<0.01$) and HDL significantly lowered ($P<0.001$). Melatonin treatment to these experimental groups accounted for a significant ($P<0.01$) improvement in TG and TC but LDL, VLDL and HDL did not record the said favorable changes. However, relative significant decrement ($P<0.001$) in LDL and VLDL and relative improvement in HDL were observed following melatonin treatment (Supplementary fig. 8). Further, mRNA levels of *CPT-1, PPARα and SREBP-1c* were significantly elevated in HFHF, JL and HFHF+JL groups ($P<0.01$). Melatonin treatment accounted for a significant decrement ($P<0.001$) in mRNA of the said genes (Fig. 6).

Melatonin resynchronises hepatic clock gene expression pattern desynchronized by HFHF and/or JL mice.

A time point study (ZT=0, 6, 12, 18, 24 h) was conducted to assess possible alterations in core clock genes (*Clock, Bmal1, Per1, Per2 and Cry2*) in liver of control and experimental groups. Both *Bmal1* and *Clock* mRNA peaked at ZT6 in liver of control mice. HFHF feeding resulted in a flattened peak of *Bmal1* and *Clock* mRNA. Melatonin treatment accounted for improvement in *Bmal1* oscillation at ZT6 whereas the clock showed peak shift from ZT6 to ZT12. The oscillations of *Per1, Per2* and *Cry2* did not show significant variations in HFHF fed mice. However, *Per1 and Cry2* oscillations were elevated at ZT18 in melatonin supplemented HFHF fed group (Fig. 7A). A positive shift in amplitude observed in circwave analysis further justified restoration of *Bmal1* oscillation by melatonin treatment (Fig. 7B). Similarity in oscillations of *Bmal1* and *Clock* genes in liver of HFHF and JL treated mice is a key observation. Oscillations of *Per1, Per2* and *Cry2* appeared to be dampened as evidenced by nearly flattened curve (Fig.7A). Exogenous melatonin appears to restore the oscillations of said genes as evidenced by the circwave analysis (Fig. 7B). Additionally, HFHF+JL group noted completely arrhythmic expression in mRNA of Bmal1, *Per1, Per2* and *Cry2*, whereas *Clock* mRNA showed phase shift from ZT6 to ZT18. Melatonin treatment preserved the diurnal variation in expression of *Bmal1, Per2* and *Cry2*, but *Per1* remained asynchronous. However, melatonin treatment resulted in moderate restoration of peak in *Clock* mRNA at ZT12 (Fig. 7A). Thus, HFHF reported change only in the positive arm of transcriptional-translational feedback loop, whereas JL and HFHF+JL resulted in more prominent disruption of circadian clock. Overall, melatonin supplementation alleviated expression of core clock gene transcripts in HFHF, JL and HFHF+JL groups with the results being most prominent in *Bmal1, Clock, Per1* and *Cry2*.

Immunoblots show melatonin induced circadian reprogramming in Clock-Bmal1 and NRF2-HO-1 of HFHF and/or JL mice.

Rhythmic oscillations of Bmal1 and Clock protein in liver of control mice showed peak at ZT6 and ZT18 respectively. HFHF diet feeding resulted in flattening of the peak of Bmal1 and a shift was seen at ZT12 in Clock proteins. Melatonin treatment to HFHF fed mice resulted in restoration of ZT6 peak of Bmal1 whereas the peak of ZT12 of Clock remained unchanged. Further, Nrf2 and Keap1 proteins showed peak at ZT6 and HO-1 peaked at ZT12 in liver of healthy mice. Feeding of HFHF diet caused flattening of ZT6 peak of Nrf2 and Keap1. Also, peak of HO-1 shifted from ZT12 to ZT6 in this group. Melatonin treatment did not result in corrections of the oscillations of Nrf2, HO-1 and Keap1 proteins wherein Nrf2 and HO-1 showed further flattening of the peaks whereas Keap1 underwent a shift from ZT6

to ZT24. JL induced significant distortion in oscillation of clock genes (Bmal1 and Clock) and HO-1 whereas, Nrf2 and Keap1 oscillations did not undergo significant changes. Melatonin treatment restored the oscillations of Bmal1 and Clock proteins at ZT6, but HO-1 oscillations were not restored. Oscillations of Nrf2 and Keap1 proteins were oblivious to the treatment schedule. A combination of HFHF+JL caused lack of oscillations in Bmal1 as evidenced by flattened curve. Also, Clock oscillation at ZT6 were unchanged but ZT18 was lacking. Further, Nrf2 and HO-1 proteins witnessed the flattening of the curve in HFHF+JL group whereas Keap1 recorded a shift from ZT6 to ZT12. Melatonin treatment could restore the ZT6 oscillation of Bmal1 and Keap1 protein and were comparable to control. Oscillations of Clock at ZT18 was restored following melatonin treatment but ZT6 was flattened. HO-1 noted a change in peak from ZT12 to ZT6 but Nrf2 was oblivious to melatonin treatment (fig. 8A and 8B).

Discussion

Circadian clock regulates array of pathophysiological processes in liver wherein epidemiological studies have highlighted implications of circadian misalignment caused by chronic jetlag in metabolic disorders including NAFLD. In our study, OA induced circadian misalignment and its subsequent impact on antioxidant regulatory genes (Nrf2, HO-1, Keap1) has thrown light on the importance of core clock genes in NAFLD. In diseases like pulmonary fibrosis and diabetes, circadian control of Nrf2 is well established [23,25], but these studies lack clarity on oscillatory pattern of said genes. Findings of the present study reveal that OA treatment to HepG2 cells leads to circadian misalignment in Nrf2 and HO-1, while exogenous administration of melatonin moderately re-entrain circadian oscillations of Nrf2 and HO-1 genes. On the other hand, therapeutic role of melatonin in re-entrainment of disturbed circadian rhythm following constant light exposure has been reported [31]. Our previous study had reported perturbations in NRF2-ARE pathway genes in HFHF induced NAFLD. Herein, our hypothesis was further validated in chronic HFHF and/or JL treated C57BL/6J mice that showed significant variations in oscillatory patterns of Nrf2, HO-1 and Keap1 (on a 24h scale) with HFHF+JL group showing maximal variations. Protein expression of Nrf2, HO-1 and Keap1 in control mice are in agreement with these published findings [21]. But variations recorded in HFHF and JL groups provide an insight on the dynamic state of hepatic antioxidant defense system under conditions of NAFLD. Nuclear transfer of Nrf2 following administration of a test therapeutant [20] or melatonin [36] is crucial for Nrf2 activation. Hence, the corrective changes obtained in the oscillatory patterns

of Nrf2 and associated genes observed herein, is attributable to the said mechanism. The re-entrainment of disturbed rhythms of antioxidant genes in HFHF+JL group provides testimony to the efficacy of therapeutic potential of melatonin.

Suprachiasmatic nuclei (SCN) in hypothalamus of mammals synchronizes subsidiary peripheral clocks in the body [37] but liver contains its own clock [38] that regulates fatty acid, glucose and Xenobiotic metabolisms. Both, food restriction and high calorie diet are known to entrain hepatic clocks; a physiological response that is independent of SCN [39]. In our study, the HFHF mediated poor circadian oscillation of hepatic core clock genes in liver are in agreement with other studies [8,11]. But the same was not observed in negative regulators (Per and Cry) suggesting that the core feedback loop was markedly reduced by HFHF feeding. On the other hand, a variety of photoperiodic regime have been experimented to induce chronodisruption, that amounts to the phase advance-phase delay (lights off at ZT4 and lights on at ZT20 respectively). The Jetlag (JL) photoperiodic schedule used herein has been reported to cause a subdued circadian oscillation of clock genes, making $Fxr^{-/-}$ mice prone to NAFLD and further leading to hepatocellular carcinoma [16]. In our study, melatonin mediated corrective changes in oscillatory pattern of clock genes in mice subjected to JL has been reported. Findings of the other research groups and the data showcased herein establishes the potency of HFHF or JL in manifesting desynchrony of clock genes, that is also a key cause in epidemiology of NAFLD. Such a combination of HFHF and JL has never been studied. Based on our findings in HFHF+JL group we hypothesize that a high calorie diet in combination with chronodisruption has a synergistic effect on core clock regulators and antioxidant related genes.

Melatonin is extensively reported for its multifaceted physiological role and also in improving hepatic pathophysiology in liver disease including NAFLD [40]. Lowered hepatic fat accumulation and corrections in physiological perturbations of fatty acid synthesis and transportation have been attributed to melatonin mediated improvement of NAFLD. In our study, observations on melatonin mediated decreased OA uptake in HepG2 cells, lowered intracellular oxidative stress and improved mitochondrial membrane potential are in agreement with other research groups [35,41] and hence forms basis of our study. Evening injections of melatonin have been associated with high degree of physiological relevance in mice [42] and hence, the same was used in our study that resulted in improved levels of AST and ALT, key lipid metabolism genes (CPT-1, PPARα, SREBP-1c) and microscopic evaluations (H&E and ORO stainings) that comprehend improved status of NAFLD in HFHF

and/or JL mice. The perturbations in Nrf2-HO-1 genes in HFHF and/or JL has never been reported and our results throw light on the same. Though melatonin treatment in HFHF, JL or HFHF+JL does not appear to accurately restore the said oscillations, the recorded observations appear to be adequate in improving the functional status of fatty liver.

Primary hepatocytes are the 'gold standard' for studying hepatic cellular metabolism because of their obvious relevance to an in vivo situation albeit, a short life span is a cause of concern. Hence, transformed cell lines derived from hepatocellular carcinoma are used as an alternative wherein; HepG2 cells are popular due to their easy availability, less variation resulting due to handling and a longer life span. But, investigation of the HepG2 proteome had revealed discrepancies related to their gluconeogenic pathway and a greater reliance on non-oxidative glucose metabolism compared with primary human hepatocytes. Alterations in the metabolic phenotype of HepG2 cells are its limitation that can be attributed to its origin from a tumor tissue [43,44]. A comparative study on oscillatory pattern of circadian clock genes in HepG2 and mouse liver cells had shown similar periodicity but variations in their dynamics [45]. Hence, in our study the HepG2 cells were used to generate a prima facie evidence on merits of melatonin in correcting OA induced circadian desynchrony whereas; the crux of the findings were based on results obtained in liver tissue of C57BL/6J mouse treated with HFHF and/or JL. Taken together, this study unravels the relevance of clock gene oscillations and Nrf2-HO-1 in liver that culminate in NAFLD (Fig. 9). The HFHF-JL synergy symbolizes the actual scenario of a lifestyle disorder and exogenous melatonin mediated corrective changes in oscillatory pattern of core clock genes and associated genes strongly implies towards use of melatonin as a therapeutant in lifestyle disorders including NAFLD.

Acknowledgement The author AJ is thankful to DST-SERB for financial assistance. Research funding under Core Research Grant (SERB EMR/2015/002001) provided by Science and Engineering Research Board (SERB), New Delhi, India to RD is duly acknowledged. Technical helps in various capacities rendered by Prof. Rajesh Singh (Biochemistry), Prof. Vihas Vasu (Zoology), DBTMSUB-ILSPARE, MSU Baroda and Dr. Kishore Rajput (Botany), MSU Baroda are duly acknowledged. Ms. Hitarthi Vyas (Technical help) is also acknowledged.

Contribution of authors AJ carried out the experiment, analyzed the data and wrote the manuscript. KKU contributed in study design and manuscript editing. AV contributed in

animal experimentation and histological analysis. KS contributed in experimentation and editing the manuscript. RVD analyzed the data, contributed and edited manuscript. All the authors revised and approved the manuscript.

Conflict of interest Authors declare no conflict of interest

Table 1. Primer sequences for quantitative PCR.

Gene Name	**Forward Primer (5'→3')**	**Reverse Primer (5'→3')**
hClock	CGAGCGCTCCCGAATTTTTA	AGGTATCTAGTGAGACTTGCC
hBmal1	GGCTCATAGATGCAAAAACTGG	CTCCAGAACATAATCGAGATG
hPer2	GACTCCTCGGCTTGAAACGG	GTGTCACCGCAGTTCAAACG
hCry2	GTGCCTCAAATCCTGACCCA	GCCTCCCACAAGATTGACGA
hPPARα	GCTTCGCAAACTTGGACCTG	GCTACCAGCATCCCGTCTTT
hSREBP1c	GCGCTCAACGGCTTCAAAAAT	AAAGTGCAATCCATGGCTCC
hCPT-1	ATCAATCGGACTCTGGAAACGG	TCAGGGAGTAGCGCATGGT
hNrf-2	CTGCCAACTACTCCCAGGTT	TGACTGAAACGTAGCCGAAGA
hHO-1	TCTTGGCTGGCTTCCTTACC	GGATGTGCTTTTCGTTGGGG
hGAPDH	GAGTCAACGGATTTGGTC	GACAAGCTTCCCGTTCTC
mClock	CACTCTCACAGCCCCACTGTA	CCCCACAAGCTACAGGAGCAG
mBmal1	ACATAGGACACCTCGCAGAA	AACCATCGACTTCGTAGCGT
mPer1	CATGACTGCACTTCGGGAGC	CTTGACACAGGCCAGAGCGTA
mPer2	GGCTTCACCATGCCTGTTGT	GGAGTTATTTCGGAGGCAAGT
mCry2	TCGGCTCAACATTGAACGAA	GGGCCACTGGATAGTGCTCT
mPPARα	TGCAAACTTGGACTTGAACG	TGATGTCACAGAACGGCTTC
mSREBP1cm	GCAGCCACCATCTAGCCTG	CAGCAGTGAGTCTGCCTTGAT
mCPT-1	CGATCATCATGACTATGCGCTA	GCCGTGCTCTGCAAACATC
mGAPDH	TGTGAACGGATTTGGCCGTA	ACTGTGCCGTTGAATTTGCC

Figure Legends

Figure 1: Schematic representation of photoperiodic regime. C57BL/6J mice of Control and HFHF groups were maintained with L:D 12:12 regime ; JL were subjected to 8h phase advance on Monday and 8h phase delay on Thursday for 16 weeks; HFHF+JL were fed with high fat high fructose (HFHF) diet and maintained on JL photoperiodic regimen.

Figure 2. Melatonin modulates oscillation of clock genes in OA induced circadian desynchrony. (A) After 2h of serum shock, HepG2 cells were treated with OA and/or melatonin for 24 h. Cells were collected for mRNA analysis at an interval for 4h between 24 to 48 h. Transcription levels were measured by RT-PCR and normalized to GAPDH. Data represented as mean±SD. *P<0.05, ***P<0.001 vs control, #P<0.05, ###P<0.001 vs OA group. n=3. (B) Circwave analysis shows correction in amplitude and peak time in HepG2 cells treated with OA+Mel.

Figure 3. Melatonin treatment favorably reduces body weight of HFHF and/or JL treated mice at the end of 16 weeks. Data represented as mean±SD ***P<0.001 vs control, ###P<0.001 vs HFHF, JL and HFHF+JL, +++P<0.001 vs HFHF and …P<0.001.

Figure 4. Exogenous melatonin treatment does not improve blood glucose levels in HFHF and/or JL exposed C57BL/6J mice. (A) Blood glucose levels at various time intervals (B) area under curve (AUC). Data represented as mean±SD. *P<0.05, **P<0.01, ***P<0.001 vs control, #P<0.05, ##P<0.01, ###P<0.001 vs HFHF, JL and HFHF+JL, +++P<0.001 vs HFHF and …P<0.001. n=6

Figure 5. Melatonin treatment improves Liver function and histopathology in HFHF and/or JL exposed mice. Graph represent (A) AST and (B) ALT levels in serum and (C) Scoring of fatty manifestation in liver Data represented as mean±SD. *P<0.05, **P<0.01, ***P<0.001 vs control, #P<0.05, ##P<0.01, ###P<0.001 vs HFHF, JL and HFHF+JL, +++P<0.001 vs HFHF and …P<0.001. n=6

Figure 6. Protective effect of melatonin on genes governing lipid metabolism in HFHF and/or JL exposed mice liver. Graphs represents mRNA expression of lipid metabolism genes as analyzed by RT-qPCR. Data represented as mean±SD. *P<0.05, **P<0.01, ***P<0.001 vs control, #P<0.05, ##P<0.01, ###P<0.001 vs HFHF,JL and HFHF+JL, +P<0.05 +++P<0.001 vs HFHF and …P<0.001.

Figure 7. Melatonin reprograms the circadian clock gene in HFHF and/or JL mice liver as evidenced by their mRNA profiles. (A)Grey shaded area indicates dark phase (ZT12 to

ZT24). Data represented as mean±SD. *P<0.05, **P<0.01, ***P<0.001 vs control, #P<0.05, ##P<0.01, ###P<0.001 vs HFHF, JL and HFHF+JL. n=4 for each time point. (B) Circwave anlaysis of clock genes in liver of HFHF and/or JL treated mice shows an improvement following melatonin treatment.

Figure 8. (A) Melatonin modulates protein expression pattern of Clock-Bmal1 and NRF2-ARE pathway genes in HFHF and/or JL exposed mice liver. (B) Densitometric analysis of western blot. Blots were normalized by β-actin as endogenous control. Grey shaded area indicates the dark phase (ZT12 to ZT24). Data represented as mean±SD. *P<0.05, **P<0.01, ***P<0.001 vs control, #P<0.05, ##P<0.01, ###P<0.001 vs HFHF, JL and HFHF+JL.

Figure 9. Schematic representation illustrating the modulatory effect of melatonin in circadian desynchrony induced by HFHF and/or JL leading to improvement in pathophysiological condition of NAFLD.

References

1. Panda S. Circadian physiology of metabolism. *Science (80-)*. 2016;354(6315):1008-1015.

2. Damiola F, Le Minh N, Preitner N, Kornmann B, Fleury-Olela F, Schibler U. Restricted feeding uncouples circadian oscillators in peripheral tissues from the central pacemaker in the suprachiasmatic nucleus. *Genes Dev*. 2000;14(23):2950-2961.

3. Partch CL, Green CB, Takahashi JS. Molecular architecture of the mammalian circadian clock. *Trends Cell Biol*. 2014;24(2):90-99.

4. Asher G, Sassone-Corsi P. Time for food: the intimate interplay between nutrition, metabolism, and the circadian clock. *Cell*. 2015;161(1):84-92.

5. Froy O. The relationship between nutrition and circadian rhythms in mammals. *Front Neuroendocrinol*. 2007;28(2-3):61-71.

6. Kohsaka A, Laposky AD, Ramsey KM, et al. High-fat diet disrupts behavioral and molecular circadian rhythms in mice. *Cell Metab*. 2007;6(5):414-421.

7. Hsieh MC, Yang SC, Tseng HL, Hwang LL, Chen CT, Shieh KR. Abnormal expressions of circadian-clock and circadian clock-controlled genes in the livers and

kidneys of long-term, high-fat-diet-treated mice. *Int J Obes*. 2010;34(2):227-239.

8. Mi Y, Qi G, Fan R, Ji X, Liu Z, Liu X. EGCG ameliorates diet-induced metabolic syndrome associating with the circadian clock. *Biochim Biophys Acta (BBA)-Molecular Basis Dis*. 2017;1863(6):1575-1589.

9. Zhou B, Zhang Y, Zhang F, et al. CLOCK/BMAL1 regulates circadian change of mouse hepatic insulin sensitivity by SIRT1. *Hepatology*. 2014;59(6):2196-2206.

10. Tong X, Zhang D, Arthurs B, et al. Palmitate inhibits SIRT1-dependent BMAL1/CLOCK interaction and disrupts circadian gene oscillations in hepatocytes. *PLoS One*. 2015;10(6):e0130047.

11. Qi G, Guo R, Tian H, et al. Nobiletin protects against insulin resistance and disorders of lipid metabolism by reprogramming of circadian clock in hepatocytes. *Biochim Biophys Acta (BBA)-Molecular Cell Biol Lipids*. 2018;1863(6):549-562.

12. Parsons MJ, Moffitt TE, Gregory AM, et al. Social jetlag, obesity and metabolic disorder: investigation in a cohort study. *Int J Obes*. 2015;39(5):842-848.

13. Khan S, Duan P, Yao L, Hou H. Shiftwork-mediated disruptions of circadian rhythms and sleep homeostasis cause serious health problems. *Int J Genomics*. 2018;2018.

14. Rudic RD, McNamara P, Curtis A-M, et al. BMAL1 and CLOCK, two essential components of the circadian clock, are involved in glucose homeostasis. *PLoS Biol*. 2004;2(11):e377.

15. Iwamoto A, Kawai M, Furuse M, Yasuo S. Effects of chronic jet lag on the central and peripheral circadian clocks in CBA/N mice. *Chronobiol Int*. 2014;31(2):189-198.

16. Kettner NM, Voicu H, Finegold MJ, et al. Circadian homeostasis of liver metabolism suppresses hepatocarcinogenesis. *Cancer Cell*. 2016;30(6):909-924.

17. Marra F, Gastaldelli A, Baroni GS, Tell G, Tiribelli C. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. *Trends Mol Med*. 2008;14(2):72-81.

18. Takaki A, Kawai D, Yamamoto K. Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH). *Int J Mol Sci*. 2013;14(10):20704-20728.

19. Kaspar JW, Niture SK, Jaiswal AK. Nrf2: INrf2 (Keap1) signaling in oxidative stress. *Free Radic Biol Med*. 2009;47(9):1304-1309.

20. Upadhyay KK, Jadeja RN, Vyas HS, et al. Carbon monoxide releasing molecule-A1 improves nonalcoholic steatohepatitis via Nrf2 activation mediated improvement in oxidative stress and mitochondrial function. *Redox Biol*. 2020;28:101314.

21. Xu Y-Q, Zhang D, Jin T, et al. Diurnal variation of hepatic antioxidant gene expression in mice. *PLoS One*. 2012;7(8):e44237.

22. Early JO, Menon D, Wyse CA, et al. Circadian clock protein BMAL1 regulates IL-1β in macrophages via NRF2. *Proc Natl Acad Sci*. 2018;115(36):E8460-E8468.

23. Lee J, Moulik M, Fang Z, et al. Bmal1 and β-cell clock are required for adaptation to circadian disruption, and their loss of function leads to oxidative stress-induced β-cell failure in mice. *Mol Cell Biol*. 2013;33(11):2327-2338.

24. Qi G, Mi Y, Fan R, Zhao B, Ren B, Liu X. Tea polyphenols ameliorates neural redox imbalance and mitochondrial dysfunction via mechanisms linking the key circadian regular Bmal1. *Food Chem Toxicol*. 2017;110:189-199.

25. Pekovic-Vaughan V, Gibbs J, Yoshitane H, et al. The circadian clock regulates rhythmic activation of the NRF2/glutathione-mediated antioxidant defense pathway to modulate pulmonary fibrosis. *Genes Dev*. 2014;28(6):548-560.

26. Cipolla-Neto J, Amaral FG, Afeche SC, Tan DX, Reiter RJ. Melatonin, energy metabolism, and obesity: a review. *J Pineal Res*. 2014;56(4):371-381.

27. Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. *Sleep Med Rev*. 2005;9(1):11-24.

28. Gonzalez A, del Castillo-Vaquero A, Miro-Moran A, Tapia JA, Salido GM. Melatonin reduces pancreatic tumor cell viability by altering mitochondrial physiology. *J Pineal Res*. 2011;50(3):250-260.

29. Pan M, Song Y, Xu J, Gan H. Melatonin ameliorates nonalcoholic fatty liver induced by high-fat diet in rats. *J Pineal Res*. 2006;41(1):79-84.

30. Sun H, Wang X, Chen J, et al. Melatonin improves non-alcoholic fatty liver disease via MAPK-JNK/P38 signaling in high-fat-diet-induced obese mice. *Lipids Health Dis*.

2016;15(1):1-8.

31. Hong F, Pan S, Xu P, et al. Melatonin orchestrates lipid homeostasis through the hepatointestinal circadian clock and microbiota during constant light exposure. *Cells*. 2020;9(2):489.

32. Cousin SP, Hügl SR, Wrede CE, Kajio H, Myers Jr MG, Rhodes CJ. Free fatty acid-induced inhibition of glucose and insulin-like growth factor I-induced deoxyribonucleic acid synthesis in the pancreatic β-cell line INS-1. *Endocrinology*. 2001;142(1):229-240.

33. Sato K, Meng F, Francis H, et al. Melatonin and circadian rhythms in liver diseases: Functional roles and potential therapies. *J Pineal Res*. 2020;68(3):e12639.

34. Liang W, Menke AL, Driessen A, et al. Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology. *PLoS One*. 2014;9(12):1-17. doi:10.1371/journal.pone.0115922

35. Mi Y, Tan D, He Y, Zhou X, Zhou Q, Ji S. Melatonin modulates lipid metabolism in HepG2 cells cultured in high concentrations of oleic acid: AMPK pathway activation may play an important role. *Cell Biochem Biophys*. 2018;76(4):463-470.

36. Wang D, Wei Y, Wang T, et al. Melatonin attenuates (-)-epigallocatehin-3-gallate-triggered hepatotoxicity without compromising its downregulation of hepatic gluconeogenic and lipogenic genes in mice. *J Pineal Res*. 2015;59(4):497-507.

37. Adamovich Y, Rousso-Noori L, Zwighaft Z, et al. Circadian clocks and feeding time regulate the oscillations and levels of hepatic triglycerides. *Cell Metab*. 2014;19(2):319-330.

38. Xu K, DiAngelo JR, Hughes ME, Hogenesch JB, Sehgal A. Interaction between circadian clocks and metabolic physiology: implications for reproductive fitness. *Cell Metab*. 2011;13(6):639.

39. Hara R, Wan K, Wakamatsu H, et al. Restricted feeding entrains liver clock without participation of the suprachiasmatic nucleus. *Genes to Cells*. 2001;6(3):269-278.

40. Sun H, Huang F, Qu S. Melatonin: a potential intervention for hepatic steatosis. *Lipids Health Dis*. 2015;14(1):1-6.

41. Das N, Mandala A, Naaz S, et al. Melatonin protects against lipid-induced mitochondrial dysfunction in hepatocytes and inhibits stellate cell activation during hepatic fibrosis in mice. *J Pineal Res*. 2017;62(4):e12404.

42. Baxi DB, Singh PK, Vachhrajani KD, Ramachandran A V. Melatonin supplementation in rat ameliorates ovariectomy-induced oxidative stress. *Climacteric*. 2013;16(2):274-283.

43. Rowe C, Gerrard DT, Jenkins R, et al. Proteome-wide analyses of human hepatocytes during differentiation and dedifferentiation. *Hepatology*. 2013;58(2):799-809.

44. Wiśniewski JR, Vildhede A, Norén A, Artursson P. In-depth quantitative analysis and comparison of the human hepatocyte and hepatoma cell line HepG2 proteomes. *J Proteomics*. 2016;136:234-247.

45. Mazzoccoli G, Rubino R, Tiberio C, et al. Clock gene expression in human and mouse hepatic models shows similar periodicity but different dynamics of variation. *Chronobiol Int*. 2016;33(2):181-190.



fsb2_21803_f1.tif



fsb2_21803_f2.tif



fsb2_21803_f3.tif



fsb2_21803_f4.tif



fsb2_21803_f5.tif



fsb2_21803_f6.tif



fsb2_21803_f7.tif



fsb2_21803_f8.tif



fsb2_21803_f9.tif